Cargando…

Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors

New chimeric inhibitors targeting the epidermal growth factor (EGFR) and histone deacetylases (HDACs) were synthesized and tested for antineoplastic efficiency in solid cancer (prostate and hepatocellular carcinoma) and leukemia/lymphoma cell models. The most promising compounds, 3BrQuin-SAHA and 3C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goehringer, Nils, Biersack, Bernhard, Peng, Yayi, Schobert, Rainer, Herling, Marco, Ma, Andi, Nitzsche, Bianca, Höpfner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395095/ https://www.ncbi.nlm.nih.gov/pubmed/34445133 http://dx.doi.org/10.3390/ijms22168432

Ejemplares similares

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Ma, Andi, et al.
Publicado: (2022)

Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
por: Bär, Sofia Isolde, et al.
Publicado: (2022)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes
por: Oberhuber, Natalie, et al.
Publicado: (2023)

New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells
por: Schaller, Eva, et al.
Publicado: (2021)

Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents
por: Nitzsche, Bianca, et al.
Publicado: (2023)

Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer
por: Steinemann, Gustav, et al.
Publicado: (2019)

Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
por: Schmitt, Florian, et al.
Publicado: (2019)

3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors
por: Bär, Sofia I., et al.
Publicado: (2022)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

Fluorinated and N-Acryloyl-Modified 3,5-Di[(E)-benzylidene]piperidin-4-one Curcuminoids for the Treatment of Pancreatic Carcinoma
por: Ghosh, Hindole, et al.
Publicado: (2023)

Editorial: Advances in molecular targeted therapies of urologic cancers
por: Nitzsche, Bianca, et al.
Publicado: (2022)

Alkylating anticancer agents and their relations to microRNAs
por: Biersack, Bernhard
Publicado: (2019)

2‐Amino‐4‐aryl‐5‐oxo‐4,5‐dihydropyrano[3,2‐c]chromene‐3‐carbonitriles with Microtubule‐Disruptive, Centrosome‐Declustering, and Antiangiogenic Effects in vitro and in vivo
por: Köhler, Leonhard H. F., et al.
Publicado: (2022)

Antiparasitic Activity of Fluorophenyl-Substituted Pyrimido[1,2-a]benzimidazoles
por: Nasr, Ibrahim S. Al, et al.
Publicado: (2023)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs
por: Biersack, Bernhard
Publicado: (2016)

A New Synthetic Curcuminoid Displays Antitumor Activities in Metastasized Melanoma
por: Kaps, Leonard, et al.
Publicado: (2023)

HDAC inhibitors and cardioprotection: Homing in on a mechanism of action
por: Weeks, Kate L.
Publicado: (2019)

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities
por: Köhler, Leonhard H. F., et al.
Publicado: (2023)

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
por: Ibrahim, Tarek S., et al.
Publicado: (2021)

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
por: Jenke, Robert, et al.
Publicado: (2021)

Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches
por: Li, Wenbo, et al.
Publicado: (2019)

HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
por: Karagiannis, Dimitris, et al.
Publicado: (2021)

Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
por: Dong, Hang, et al.
Publicado: (2019)

Synthesis, Characterization and Biological Evaluation of Novel Dihydropyranoindoles Improving the Anticancer Effects of HDAC Inhibitors
por: Bingul, Murat, et al.
Publicado: (2020)

New 4,5-Diarylimidazol-2-ylidene–iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells
por: Schleser, Sebastian W., et al.
Publicado: (2023)

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
por: Cross, Jasmine M., et al.
Publicado: (2020)

Synthesis and Anticancer Activities of Pyrazole–Thiadiazole-Based EGFR Inhibitors
por: Kurban, Berkant, et al.
Publicado: (2023)

Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
por: Farhan, Mohd, et al.
Publicado: (2019)

Guided Antitumoural Drugs: (Imidazol‐2‐ylidene)(L)gold(I) Complexes Seeking Cellular Targets Controlled by the Nature of Ligand L
por: Bär, Sofia I., et al.
Publicado: (2021)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019)

Novel Anticancer NHC*-Gold(I) Complexes Inspired by Lepidiline A
por: Curran, Danielle, et al.
Publicado: (2020)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Synthesis and Evaluation of C15 Triene Urushiol Derivatives as Potential Anticancer Agents and HDAC2 Inhibitor
por: Qi, Zhiwen, et al.
Publicado: (2018)

Revisiting the anticancer properties of phosphane(9-ribosylpurine-6-thiolato)gold(I) complexes and their 9H-purine precursors
por: Kober, Luisa, et al.
Publicado: (2022)

HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
por: Chou, Chia-Wei, et al.
Publicado: (2011)

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
por: Toutah, Krimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ghgmsimqunf3m9p7k6dpkl9ib5